CONSTRUCTION OF STRAIN-PRODUCER OF CHEMERIC PROTEIN CONTAINING HUMAN ANNEXIN AND BACTERIAL ADENOSINE DEAMINASE
Abstract
Malignant tumors possess the mechanisms allowing one to evade the degradation of tumor-carrier by the immune system. One of the mechanisms is the formation of a tumor immunosuppressing microenvironment acted upon by extracellular adenosine. Earlier, we proposed the idea to eliminate a cancer protection barrier from the host cell immunity using adenosine deaminase fused with annexin A5. The conducted study resulted in the first development of the strain Escherichia coli producing the chimeric protein structurally composed of human annexin A5 and homologous adenosine deaminase. The generating capacity of the obtained microbial strain with respect to chimeric protein was 18 mg/l of culture fluid. 13 mg of highly purified chimeric protein showing the adenosine deaminase activity was produced. The adenosine deaminase productivity of the strain equaled 7.1 µmol/min/ml of culture fluid. The obtained chimeric protein is intended for a further investigation as a promising cancerostatic agent.
About the Authors
A. B. Bulatovski
Institute of Microbiology of the National Academy of Sciences of Belarus
Belarus
Belarus
Junior researcher
S. V. Kvach
Institute of Microbiology of the National Academy of Sciences of Belarus
Belarus
Belarus
Ph. D. (Biology), Leading researcher
L. A. Eroshevskaya
Institute of Microbiology of the National Academy of Sciences of Belarus
Belarus
Belarus
Ph. D. (Biology), Leading researcher
A. I. Zinchenko
Institute of Microbiology of the National Academy of Sciences of Belarus
Belarus
Belarus
Corresponding Member, D. Sc. (Biology), Professor, Head of the Laboratory
References
1. Sukonko О. G. Present state and prospects of oncology in Republic of Belarus. Onkologicheskii zhurnal = Oncological Journal, 2011, vol. 5, no. 4, pp. 5–18 (in Russian).
2. Lichtenstein А. V. Cancer research: A hurdle race. Biochemistry, 2014, vol. 79, no. 5, pp. 385–390. doi.org/10.1134/ s0006297914050010
3. Sverdlov E. D. Genetic surgery – a right strategy to attack cancer. Current Gene Therapy, 2011, vol. 11, no. 6, pp. 501– 531. doi.org/10.2174/156652311798192842
4. Imyanitov Е. N. Molecular mechanisms of tumoral body height. Voprosy onkologii = Problems in oncology, 2010, vol. 56, no. 2, pp. 117–128 (in Russian).
5. Kushlinskii N. Е., Nemtsova М. V. Molecular biological characteristics of cancer. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences, 2014, vol. 69, no. 1–2, pp. 5–15 (in Russian).
6. Sverdlov E. D. Multidimensional complexity of cancer. Simple solutions are needed. Biochemistry, 2016, vol. 81, no. 7, pp. 731–738. doi.org/10.1134/s0006297916070099
7. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell, 2011, vol. 144, no. 5, pp. 646–674. doi. org/10.1016/j.cell.2011.02.013
8. Joyce J. A., Fearon D. T. T-cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015, vol. 348, no. 6230, pp. 74–80. doi.org/10.1126/science.aaa6204
9. Vaupel P., Mayer A. Hypoxia-driven adenosine accumulation: a crucial microenvironmental factor promoting tumor progression. Advances in Experimental Medicine and Biology, 2016, vol. 876, pp. 177–183. doi.org/10.1007/978-1-4939-3023-4_22
10. Ohta A., Gorelik E., Prasad S. J., Ronchese F., Lukashev D., Wong M. K., Huang X., Caldwell S., Liu K., Smith P., Chen J. F., Jackson E. K., Apasov S., Abrams S., Sitkovsky M. A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, vol. 103, no. 35, pp. 13132–13137. doi. org/10.1073/pnas.0605251103
11. Zinchenko А. I. Adenosine as a potential target for cancer biotherapy. Vestsi Natsyyanal’nai akademii navuk Belarusi. Seryya biyalagichnykh navuk = Proceedings of the National Academy of Sciences of Belarus, biological series, 2016, no. 4, pp. 118–128 (in Russian).
12. Van Rite B. D., Lazrak Y. A., Pagnon M. L., Palwai N. R., Neves F. F., McFetridge P. S., Harrison R. G. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Letters, 2011, vol. 301, no. 2, pp. 177–184. doi. org/10.1016/j.canlet.2010.11.013
13. Krais J. J. De Crescenzo O., Harrison R. G. Purine nucleoside phosphorylase targeted by Annexin V to breast cancer vasculature for enzyme prodrug therapy. PLoS ONE, 2013, vol. 8, no. 10, e76403. doi.org/10.1371/journal.pone.0076403
14. Guillen K. P., Ruben E. A., Virani N., Harrison R. G. Annexin-directed β-glucuronidase for the targeted treatment of solid tumors. Protein Engineering Design and Selection, 2017, vol. 30, no. 2, pp. 85–94. doi.org/10.1093/protein/gzw063
Review
Views: 679
Email this article 